References of "Rozenberg, Serge"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEtat de la contraception en 2016
Manigart, Yannick; BELIARD, Aude ULg; Rozenberg, Serge et al

in Revue Médicale de Bruxelles (2016), 37

Introduction: The Pill and and other forms of hormonal contraception, if taken correctly, are very effective and safe for millions of women, but since a few years, due to debates and controversies about ... [more ▼]

Introduction: The Pill and and other forms of hormonal contraception, if taken correctly, are very effective and safe for millions of women, but since a few years, due to debates and controversies about third- and fourth-generation pills, other options have gained in popularity. Objectives: to provide a review of oestroprogestative contraception (OP), progestative contraception, IUDs with a focus on their advantages and side-effects according to the specific needs of women.Methods: Literature review and lessons learned from clinical practice.Results: the importance of family and individual history, the life-style and socio-economic conditions are critical factors for advising women of the 15 contraceptive choices available to them. The risk/benefit ratio of OP contraception needs a yearly follow-up. The progestative contraception is the preferred option for women who have contraindication for estrogen, are older than forty, and/or have risk factors such as a history of venous thromboembolism, overweight and smoking. The IUD is well tolerated and causes few side effects. Among the other contraceptive methods, sterilization and diaphragms are briefly discussed. Conclusions: Among the many safe and effective contraceptive methods, it is important for general practitioners to know the advantages and the side effects of each method, as well as the specific conditions of the woman, to propose the best options available. In case of difficulties of follow up or adherence to daily uptake, in particular among adolescents, long-acting methods such as IUD or implants are preferable. [less ▲]

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailEffects of Dairy Products Consumption on Health: Benefits and Beliefs-A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
Rozenberg, Serge; Body, Jean-Jacques; Bruyère, Olivier ULg et al

in Calcified Tissue International (2016), 98(1), 1-17

Dairy products provide a package of essential nutrients that is difficult to obtain in low-dairy or dairy-free diets, and for many people it is not possible to achieve recommended daily calcium intakes ... [more ▼]

Dairy products provide a package of essential nutrients that is difficult to obtain in low-dairy or dairy-free diets, and for many people it is not possible to achieve recommended daily calcium intakes with a dairy-free diet. Despite the established benefits for bone health, some people avoid dairy in their diet due to beliefs that dairy may be detrimental to health, especially in those with weight management issues, lactose intolerance, osteoarthritis, rheumatoid arthritis, or trying to avoid cardiovascular disease. This review provides information for health professionals to enable them to help their patients make informed decisions about consuming dairy products as part of a balanced diet. There may be a weak association between dairy consumption and a possible small weight reduction, with decreases in fat mass and waist circumference and increases in lean body mass. Lactose intolerant individuals may not need to completely eliminate dairy products from their diet, as both yogurt and hard cheese are well tolerated. Among people with arthritis, there is no evidence for a benefit to avoid dairy consumption. Dairy products do not increase the risk of cardiovascular disease, particularly if low fat. Intake of up to three servings of dairy products per day appears to be safe and may confer a favourable benefit with regard to bone health. [less ▲]

Detailed reference viewed: 37 (20 ULg)
Full Text
Peer Reviewed
See detailHealth Technology Assessment in Osteoporosis.
Hiligsmann, Mickaël ULg; Kanis, John A.; Compston, Juliet et al

in Calcified Tissue International (2013), 93(1), 1-14

We review the various aspects of health technology assessment in osteoporosis, including epidemiology and burden of disease, and assessment of the cost-effectiveness of recent advances in the treatment of ... [more ▼]

We review the various aspects of health technology assessment in osteoporosis, including epidemiology and burden of disease, and assessment of the cost-effectiveness of recent advances in the treatment of osteoporosis and the prevention of fracture, in the context of the allocation of health-care resources by decision makers in osteoporosis. This article was prepared on the basis of a symposium held by the Belgian Bone Club and the discussions surrounding that meeting and is based on a review and critical appraisal of the literature. Epidemiological studies confirm the immense burden of osteoporotic fractures for patients and society, with lifetime risks of any fracture of the hip, spine, and forearm of around 40 % for women and 13 % for men. The economic impact is also large; for example, Europe's six largest countries spent <euro>31 billion on osteoporotic fractures in 2010. Moreover, the burden is expected to increase in the future with demographic changes and increasing life expectancy. Recent advances in the management of osteoporosis include novel treatments, better fracture-risk assessment notably via fracture risk algorithms, and improved adherence to medication. Economic evaluation can inform decision makers in health care on the cost-effectiveness of the various interventions. Cost-effectiveness analyses suggest that the recent advances in the prevention and treatment of osteoporosis may constitute an efficient basis for the allocation of scarce health-care resources. In summary, health technology assessment is increasingly used in the field of osteoporosis and could be very useful to help decision makers efficiently allocate health-care resources. [less ▲]

Detailed reference viewed: 30 (11 ULg)
Full Text
See detailNécessité de nouveaux critères de remboursement pour traiter l'ostéoporose en Belgique
Bruyère, Olivier ULg; Bergmann, Pierre; Body, Jean-Jacques et al

in Ortho-Rhumato (2012), 10(5), 3

Detailed reference viewed: 35 (4 ULg)
Full Text
Peer Reviewed
See detailUtility audit of Belgian DXA centers
Goemaere, S.; Bergman, P.; Body, J. J. et al

in Osteoporosis International (2008, April), 19(Suppl.1), 205

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailBelgian bone specialists are eagerly looking to the availability of new medications in osteoporosis
Goemaere, S.; Bergmann, P.; Body, J. J. et al

in Osteoporosis International (2006, March), 17(Suppl.1), 27

Detailed reference viewed: 10 (0 ULg)